PlumX Metrics
Embed PlumX Metrics

Acute Flare of Bullous Pemphigus with Pembrolizumab Used for Treatment of Metastatic Urothelial Cancer

Journal of Immunotherapy, ISSN: 1537-4513, Vol: 41, Issue: 1, Page: 42-44
2018
  • 15
    Citations
  • 0
    Usage
  • 33
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Article Description

In the past decade, the resurgence of immunotherapy has changed the landscape of cancer therapy. Checkpoint inhibitors targeting cytotoxic T-lymphocyte antigen-4, programmed death-1 on lymphocytes, and programmed death ligand-1 on tumors cells are currently utilized in the management of several cancers. These agents are double-edged sword with the positive effect being robust antitumor response but on the other side they can throttle up the normal immunologic homeostasis in a negative way, leading to adverse autoimmune toxicities. These adverse toxicities are frequent if patients have active autoimmune disorders. Here, we report a rare case of quiescent bullous pemphigoid which flared after initiation of pembrolizumab, a programmed death ligand-1 inhibitor.

Bibliographic Details

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know